Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to developing a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high clinical response rates with potentially curative efficacy.  The company is currently developing SYNC-T, a novel platform technology that uses a drug/device combination therapy. The platform is designed to achieve personalized T cell education, enabling the immune system to recognize and attack cancer throughout the body.  The first 2 candidates, SV-101 and SV-102 are currently in Phase 1 trials.